Spago Nanomedical AB (OSTO:SPAGO) Total Long-Term Assets: kr0.83 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OSTO:SPAGO Spago Nanomedical AB OSTO:SPAGO
32 GF Score
Price kr0.11
GF Value kr0.03
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Spago Nanomedical AB Total Long-Term Assets?

Spago Nanomedical AB OSTO:SPAGO +5.80% 32 Total Long-Term Assets is kr0.83 Mil as of Jun. 2026. GuruFocus rates OSTO:SPAGO with a GF Score™ of 32/100 and a GF Value™ of kr0.03 (Significantly Overvalued). The stock has 4 warning signs investors should review.

Total Long-Term Assets includes Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets. Spago Nanomedical AB's Total Long-Term Assets for the quarter that ended in Jun. 2026 was kr0.83 Mil.

Spago Nanomedical AB Total Long-Term Assets Related Terms

Spago Nanomedical AB Total Long-Term Assets Historical Data

* Premium members only.

The historical data trend for Spago Nanomedical AB's Total Long-Term Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Spago Nanomedical AB Total Long-Term Assets Chart

Spago Nanomedical AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Long-Term Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 137.24 140.71 1.08 1.00 0.75

Spago Nanomedical AB Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Total Long-Term Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.77 0.71 0.75 0.79 0.83
OSTO:SPAGO
32GF Score
Spago Nanomedical AB OSTO:SPAGO
Total Long-Term Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Spago Nanomedical AB Total Long-Term Assets Calculation

Total Long-Term Assets are the sum of the carrying amounts of all assets that are expected to be realized in cash, sold or consumed longer than one year. It includes Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets.

Frequently Asked Questions Learn more about Total Long-Term Assets →
What does a Total Long-Term Assets of kr0.83 Mil mean?
Spago Nanomedical AB (OSTO:SPAGO) has a Total Long-Term Assets of kr0.83 Mil as of Jun. 2026. Total Long-Term Assets are assets that are expected to be realized in cash, sold or consumed longer than one year. View historical data on Spago Nanomedical AB and its competitors.
Is Spago Nanomedical AB's Total Long-Term Assets too high?
Spago Nanomedical AB's current Total Long-Term Assets is kr0.83 Mil. Overall, Spago Nanomedical AB has a GF Score™ of 32/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Spago Nanomedical AB's Total Long-Term Assets compare to VRTX and REGN?
Spago Nanomedical AB's Total Long-Term Assets of kr0.83 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Long-Term Assets for a Biotechnology company?
A good Total Long-Term Assets depends on the Biotechnology industry context. However, Total Long-Term Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Long-Term Assets mean?
A high Total Long-Term Assets can signal that a stock is expensive relative to its fundamentals. Total Long-Term Assets are assets that are expected to be realized in cash, sold or consumed longer than one year. View historical data on Spago Nanomedical AB and its competitors. Spago Nanomedical AB's current Total Long-Term Assets is kr0.83 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Spago Nanomedical AB stock overvalued right now?
Based on GuruFocus' analysis, Spago Nanomedical AB (OSTO:SPAGO) is currently considered Significantly Overvalued. The stock's GF Value™ is kr0.03, compared to a current price of kr0.11 — trading 265% above its estimated fair value. The current Total Long-Term Assets is kr0.83 Mil. Spago Nanomedical AB's overall GF Score™ is 32/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Long-Term Assets calculated?
Total Long-Term Assets is calculated from a company's financial statements. For Spago Nanomedical AB (OSTO:SPAGO), the current Total Long-Term Assets is kr0.83 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Spago Nanomedical AB (OSTO:SPAGO) Overvalued in 2026?

Based on GuruFocus' analysis, Spago Nanomedical AB stock appears to be overvalued. The current stock price of kr0.11 is trading 265% above its estimated GF Value™ of kr0.03. GuruFocus considers Spago Nanomedical AB to be Significantly Overvalued.

Key valuation signals for OSTO:SPAGO:

  • Total Long-Term Assets: kr0.83 Mil
  • GF Value™: kr0.03 vs. price of kr0.11 (265% above fair value)
  • GF Score™: 32/100 with 4 warning signs

No single metric tells the full story. See the OSTO:SPAGO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Spago Nanomedical AB Business Description

Address Scheelevagen 22, Lund, SWE, SE-223 63
Spago Nanomedical AB is a nanomedicine company in the field of cancer diagnosis and treatment. The company's product includes SpagoPix and Tumorad. The SpagoPix product aims to improve cancer diagnosis with magnetic resonance imaging through the previous detection of tumors and metastases. The Tumorad products focus on the development of a completely new form of radionuclide therapy for tumor-selective radiation therapy of cancer. The company's development projects are based on a platform of polymeric materials with various properties for the precise diagnosis and treatment of life-threatening and debilitating diseases.
32GF Score

Get the complete analysis for OSTO:SPAGO

Total Long-Term Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr0.11
Price
kr0.03
GF Value